AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Anthropic’s Deal With Coefficient Bio Could Mark a Turning Point for Pharma AI
A Pharma Voice analysis argues that Anthropic’s deal with Coefficient Bio may be more than a partnership headline. It could indicate that frontier AI companies are now embedding directly into drug discovery workflows in ways that may reshape how pharma evaluates model providers.
Eli Lilly Deepens Its AI Drug Discovery Bet with Expanded Insilico Partnership
Eli Lilly is expanding its partnership with Insilico Medicine, reinforcing the view that big pharma sees AI-driven discovery as a strategic capability, not a side experiment. The deal is also a sign that established drugmakers increasingly prefer to partner for AI advantage rather than build everything internally.
Imaging Vendor Consolidation Is Reshaping the AI Radiology Market
Radiology Business reports on a vendor merger expected to affect millions of scans, alongside concerns that radiologists are losing market share and news that GE is expanding its partnership with RadNet. The story highlights how AI in imaging is increasingly being shaped by platform consolidation and channel control, not just algorithms.
GE HealthCare and RadNet’s DeepHealth Expand Their Breast Screening AI Push
GE HealthCare and RadNet's DeepHealth are deepening their collaboration around AI-powered breast cancer screening. The deal underscores how major imaging players are turning breast cancer into the commercial beachhead for enterprise AI.
BullFrog AI Partnership Highlights the New Pressure on Smaller Discovery Platforms
BullFrog AI’s newly announced drug-discovery partnership underscores how smaller AI companies are seeking validation through targeted collaborations rather than sweeping platform claims. The move reflects a broader market reality: in healthcare AI, commercial credibility increasingly comes from proving fit on specific programs.
Insilico-Lilly deal shows big pharma still sees AI as a pipeline multiplier, not a side bet
A reported multibillion-dollar deal between Insilico Medicine and Eli Lilly underscores continued pharmaceutical appetite for AI-enabled drug discovery. The scale suggests AI is being valued not as experimental tooling but as a potentially material lever on pipeline speed, hit quality, and portfolio optionality.
GE HealthCare and Stanford deepen ties as imaging AI competition shifts to co-development
GE HealthCare and Stanford Radiology are expanding their collaboration with a new center of excellence, underscoring how the imaging AI market is moving beyond standalone algorithms toward long-term clinical development partnerships. The deal matters because vendors increasingly need health-system validation, workflow integration, and data access as much as model performance.
Insilico Deepens CNS Ambitions With Tenacia Expansion Worth Up to $94.75 Million
Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven CNS partnership in a deal valued at up to $94.75 million. The agreement underscores both sustained investor interest in AI-enabled pipelines and the continued appeal of high-need neuropsychiatric and neurological targets despite their development risk.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.